Rabeprazole

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Rabeprazole
   1. Pharmacist Assessment Report
   2. Rabeprazole: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Rabeprazole: Known uses and market status in Canada

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidate indications for Rabeprazole. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The two known uses are relations recorded in the knowledge graph; no approval was found for them.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	2
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 8 of 8)
Number of DINs	8 (marketed: 8)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
Smouldering systemic mastocytosis
lymphoadenopathic mastocytosis with eosinophilia

Canada Market Information

Licence	Product	Dosage form	Status
02385449	RABEPRAZOLE		Valid
02356538	RABEPRAZOLE EC		Valid
02385457	RABEPRAZOLE		Valid
02314177	SANDOZ RABEPRAZOLE		Valid
02356511	RABEPRAZOLE EC		Valid
02243796	PARIET, ENTERIC-COATED TABLET 10MG		Valid
02243797	PARIET, ENTERIC-COATED TABLET 20MG		Valid
02314185	SANDOZ RABEPRAZOLE		Valid

Safety Considerations

• Disease-level contraindication signals (knowledge graph, not label text): liver disease, gallbladder disease, osteoporosis, postmenopausal osteoporosis, bone fracture.
• Drug Interactions: 100 interactions were identified in the database queried. Among those reviewed, the main ones are:
  • Major: acalabrutinib, atazanavir
  • Moderate: for example aminoglycosides (amikacin), amphotericin B formulations, amphetamine, apalutamide, aprepitant, armodafinil, bosutinib, thiazide diuretics (bendroflumethiazide, benzthiazide), anisindione
  • Minor: acetylsalicylic acid, axitinib

Please refer to the package insert for the official warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---